Recent Posts

Potential Industry Effects from COVID-19 Vaccine Candidates

Posted by Dianne Dotson on Nov 10, 2020 1:24:14 PM

The COVID-19 pandemic spurred several organizations and companies around the world to try and find a working vaccine candidate within a relatively short period of time. On November 9, 2020, Pfizer and BioNTech [Pfizer Press Release] announced their vaccine candidate had achieved a success rate of 90% in their first efficacy analysis.


What a Vaccine Candidate Is and Is Not

A vaccine candidate is not a cure. It is a potential vaccine. Typically, a vaccine candidate requires at least a few years of clinical trial phases to test efficacy and assess any risks.

Given the short timeframe of events in the COVID-19 pandemic, a push for fast tracking of vaccines has taken place in various parts of the world. The goal is to make a vaccine that prevents the disease COVID-19 from developing.

In the case of Pfizer/BioNTech, their vaccine candidate passed its first interim efficacy analysis by preventing COVID-19 development in participants with no evidence of prior SARS-CoV-2 infection. The study involved nearly 44,000 participants, a robust number, and no serious safety concerns were observed. As of this writing, additional safety and efficacy data is being collected.

According to Pfizer,

The Phase 3 clinical trial of BNT162b2 began on July 27 and has enrolled 43,538 participants to date, 38,955 of whom have received a second dose of the vaccine candidate as of November 8, 2020. Approximately 42% of global participants and 30% of U.S. participants have racially and ethnically diverse backgrounds. The trial is continuing to enroll and is expected to continue through the final analysis when a total of 164 confirmed COVID-19 cases have accrued.” At the time of the news release, Pfizer declared that 94 of the nearly 44,000 participants became ill from COVID-19.

Once safety benchmarks are met, the companies plan to submit the vaccine for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA), with a slated timeline of late November 2020. The FDA had set a goal of 50% efficacy for vaccine candidates for emergency use. Clearly, 90% efficacy exceeded expectations.

The news was met with cautious jubilance, signaling the first workable vaccine (with adequate clinical trial phases) may be in the hands of medical professionals by 2021. Even as COVID-19 cases skyrocket in the U.S. and around the globe, there is hope. And this is only one of several potential vaccine candidates in the pipeline. Still, this is an early candidate.


Now for Some Caveats

This new vaccine candidate is not available for use yet. It is not known when it might become available for everyday citizens who are not healthcare workers or at elevated risk.

Experts cautioned that we still face an alarming period of time until such day arrives, and that measures to prevent COVID-19 spread must continue (mask wearing, social distancing, washing, etc.).


Thoughts on Industry Effects from COVID-19 Vaccine Candidates

According to the Regulatory Affairs Professionals Society (RAPS) COVID-19 vaccine tracker [RAPS Vaccine Tracker], two other vaccine candidates have been approved, without having entered Phase 3 clinical trials. Dozens of other candidates are being developed around the world.

When the FDA approves the usage of an efficacious vaccine for the public, does that mean work stops on all the others? Assuredly not. Efficacy is a must; affordability must also be paramount to help end the pandemic globally. The World Health Organization (WHO) created the COVAX initiative to address this need.

Essentially, the race for a vaccine is more of a marathon, not a sprint. Multiple vaccines necessitate multiple trials, and real-world vaccination, while not imminent, is hoped to arrive before long. The usual cautions apply: safety is paramount, and the entire infrastructure of development may seem labyrinthine on this grand scale.

Given Pfizer’s highly successful candidate and the broad work on other candidates, clearly we have entered an immunology golden age. It must also be postulated that non-COVID related discoveries may be made in the process as well.

It is entirely possible that new treatments for both communicable and non-communicable diseases will evolve during this unprecedented effort. The biotechnology and pharmaceutical industries stand on the cusp of saving more lives and decreasing morbidities for years to come. As such, every connection among the industry, from laboratory supplies to calibration services, software, and more will prove to be in greater demand than ever.

Beyond a golden age of immunology, a golden age of science may be upon us.



Pfizer: PFIZER and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study

Regulatory Affairs Professionals Society (RAPS): COVID-19 vaccine tracker

New York Times: Pfizer’s Covid Vaccine: 11 Things You Need to Know

Read More

Topics: covid19, pfizer, biontech, vaccine, coronavirus

Electronic Pipette Calibration

Posted by Andrew on Dec 3, 2018 7:12:46 AM

Accuracy is of paramount importance in scientific research and lab work. Accuracy in your lab begins with having correctly calibrated pipettes. Different pipette calibration plans are available to meet the varied needs of different labs. It is important to know what level of pipette calibration your lab requires to pick the correct plan to meet your needs. All labs and scientists require accuracy from their pipettes, but some require more stringent regulatory compliance standards than others. Most pipette calibration service providers offer a number of different pipette calibration levels, as well as offering pipette repair.

Read More

Topics: electronic pipette, calibration, obe

MEDICA 2018 – Oxford Lab Products is Coming to Dusseldorf!

Posted by Andrew on Nov 5, 2018 8:04:19 AM

Read More

Topics: Tradeshow, IBecameAScientistBecause, Medica, Medica2018

Three Oxford Lab Products That are Ideal for Performing ELISA Assays

Posted by Andrew on Oct 18, 2018 7:03:21 AM

When you are running your ELISAs and biological assays on multi-well plates, you need the best equipment available to you. The right products will not only ensure you get reliable and repeatable results every time, but they will also minimize your time spent at the bench. Below are three great products from Oxford that can be of enormous assistance when performing multi-well plate assays. Check them out below and see how we can improve your ELISA performance today!

Read More

Topics: Assay, Consumables, Tubes, Plate Shaker, ELISA, Equipment, Pipettes

Avoid Repetitive Strain Injury with Ergonomic Pipetting

Posted by Andrew on Oct 4, 2018 5:57:18 AM

Repetitive Strain Injury (RSI) is a term used to describe pain or injury – usually of the wrist – from repetitive movements or overuse of an instrument e.g. a pipette. Long hours of pipetting and lab work can lead to RSI if proper preventative steps are not taken. Educate yourself and your lab group in RSI so that you can all reduce your chances of experiencing RSI in the future.

Read More

Topics: RSI, Repetitive Strain Injury, Ergonomics

AACC 2018 – Oxford Lab Products is Coming Back to AACC Again This Year!

Posted by Andrew on Jul 26, 2018 4:12:41 AM

Where: Booth #4417, McCormick Place Chicago, USA

Conference Link:

Exhibit Dates: 29th Jul – 02nd Aug 2018


Read More

Topics: AACC, AACC2018, Tradeshow, IBecameAScientistBecause

Subscribe to Email Updates